Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Subcutaneous Nivolumab Sustains Comparable Efficacy, Safety to IV Formulation in Advanced ccRCC

April 10th 2025

Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

Tailored Interventions Are Needed to Reduce Barriers to Breast Cancer Screening in Jordan

April 10th 2025

A study identified individual and non-individual factors as barriers to breast cancer screening for women in Jordan.

Dr Dholaria on the Rationale for Investigating P-BCMA-ALLO1 in R/R Myeloma

April 10th 2025

Bhagirathbhai Dholaria, MBBS, discusses the rationale and evolving investigation of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma.

Dr Bando on Safety of TAS-102 in MRD+ Resected CRC

April 9th 2025

Hideaki Bando, MD, PhD, discusses the safety of trifluridine/tipiracil in patients with MRD following resection of CRC.

Expanded FDA Approval Broadens the Role of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC

April 9th 2025

Michael J. Morris, MD, discusses the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive mCRPC.

SON-1010 Plus Atezolizumab Is Safe, Displays Preliminary Efficacy in Platinum-Resistant Ovarian Cancer

April 9th 2025

SON-1010 plus atezolizumab was safe and showed clinical activity in platinum-resistant ovarian cancer and other advanced solid tumors.

FDA Clears ZEISS INTRABEAM 700 for Intraoperative Radiation Therapy in Neuro-Oncology & Breast Cancer

April 9th 2025

The ZEISS INTRABEM 700 platform received 510(k) clearance from the FDA for use in neuro-oncology and breast cancer surgery.

Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients

April 9th 2025

An independent DSMB found MaaT033 to have a favorable safety profile in patients with hematologic malignancies undergoing allo-HSCT in the PHOEBUS trial.

Dr Dumbrava on the Rationale for Evaluating Rezatapopt in TP53 Y220C–Mutated Ovarian Cancer

April 8th 2025

Ecaterina Dumbrava, MD, discusses the rationale and clinical development of rezatapopt in ovarian cancer and other solid tumors harboring TP53 Y220C mutations.

Dr Yu on Factors for PARP Inhibitor Decision-Making in Metastatic Prostate Cancer

April 8th 2025

Evan Ya-Wen Yu, MD, discusses considerations surrounding the tolerability of PARP inhibitors and how their adverse effect profiles influence treatment decisions in metastatic prostate cancer.

Dr Randall on a Survey Outlining Surgical Trial Candidates With RCC and Proximal Femoral Metastases

April 8th 2025

Lor Randall, MD, FACS, on a global survey regarding enrollment criteria for a trial evaluating surgical resection for proximal femur metastases.

Roswell Park-Led Research Reveals a Hidden Vulnerability of Lung Cancer

April 8th 2025

Sayan Chakraborty, PhD and team focus on targeting agrin, a protein that promotes treatment resistance/relapse.

AR Pathway Inhibition Refines Prostate Cancer Treatment Strategies: With Neal Shore, MD, FACS

April 7th 2025

Dr Shore discusses advances that have been achieved with AR-directed agents in prostate cancer and considerations for the optimal use of these agents.

Bel-Sar Shows Tolerability and Preliminary Antitumor Activity in NMIBC

April 7th 2025

Belzupacap sarotalocan demonstrated a favorable safety profile and early signs of biological activity in patients with NMIBC.

Dr Zonder on the Epidemiology of Multiple Myeloma

April 7th 2025

Jeffrey Zonder, MD, discusses the current epidemiological landscape of multiple myeloma in the United States.

Dr Ghia on Fixed-Duration Ibrutinib Plus Venetoclax in First-Line CLL

April 7th 2025

Paolo Ghia, MD, PhD, discusses long-term data for fixed-duration ibrutinib plus venetoclax in chronic lymphocytic leukemia.

VXM01 Plus Avelumab Is Safe and Shows Preliminary Clinical Activity in Recurrent Glioblastoma

April 7th 2025

The combination of VXM01 and avelumab was well tolerated and has the potential to generate clinically meaningful responses in recurrent glioblastoma.

Dr Randall on How Mouse Models Provide Valuable Insights in Preclinical Sarcoma Research

April 7th 2025

R. Lor Randall, MD, FACS, discusses how immunodeficient mouse models support mechanistic and therapeutic discovery in rare sarcoma subtypes.

EC Expands SC Daratumumab’s Indication for Use in All Transplant Eligibility Settings in Newly Diagnosed Myeloma

April 7th 2025

The European Commission approved subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma, regardless of transplant eligibility.

Subcutaneous Amivantamab Wins EU Approval in Multiple EGFR+ Advanced NSCLC Indications

April 7th 2025

The European Commission has approved subcutaneous amivantamab in multiple indications in advanced EGFR-mutant non–small cell lung cancer.